Treatment of severe postRYGB hyperinsulinemic hypoglycemia with pasireotide: A comparison with octreotide on insulin, glucagon, and GLP-1
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Pasireotide inhibited GLP-1 and insulin release more effectively than octreotide, resulting in improved control of postprandial hyperinsulinemic hypoglycemia after a gastric bypass.
“A recent case report demonstrated that pasireotide inhibited GLP-1 and insulin release more effectively than octreotide, resulting in improved control of postprandial hyperinsulinemic hypoglycemia after a gastric bypass (100).”
From Dumping syndrome after esophageal, gastric or bariatric surgery: Pathophysiology, diagnosis, and management (2017) · cites this paper as [100]
Cites
Bariatric Surgery versus Conventional Medical Therapy for Type 2 Diabetes
Mingrone, G., Panunzi, S., De Gaetano, A., Guidone, C., Iaconelli, A., Leccesi, L., Nanni, G., Pomp, A., Castagneto, M., Ghirlanda, G., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200111 · Cited by 1,791 · see citing works
Marsk, R., Jonas, E., Rasmussen, F., & Näslund, E. (2010) · Diabetologia · doi:10.1007/s00125-010-1798-5 · Cited by 273 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
van Beek, A. P., Emous, M., Laville, M., & Tack, J. (2017) · Obesity Reviews · doi:10.1111/obr.12467 · Cited by 288 · see citing works
“A recent case report demonstrated that pasireotide inhibited GLP-1 and insulin release more effectively than octreotide, resulting in improved control of postprandial hyperinsulinemic hypoglycemia after a gastric bypass (100).”
BackgroundCongenital hyperinsulinism: current status and future perspectives
Yorifuji, T. (2014) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2014.19.2.57 · Cited by 156 · see citing works
Clinical practice guidelines for congenital hyperinsulinism
Yorifuji, T., Horikawa, R., Hasegawa, T., Adachi, M., Soneda, S., Minagawa, M., Ida, S., Yonekura, T., Kinoshita, Y., Kanamori, Y., et al. (2017) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.26.127 · Cited by 74 · see citing works
“Novel therapies for CHI include long-acting octreotides (119), GLP1 receptor antagonists (120), Lanreotide (121, 122), insulin receptor antagonists (123), Pasireotide (124), ω3 unsaturated fatty acids (125), or mTOR inhibitors (126).”
BackgroundØhrstrøm, C. C., Worm, D., Højager, A., Andersen, D., Holst, J. J., Kielgast, U. L., & Hansen, D. L. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13796 · Cited by 72 · see citing works
Hypoglycemia in everyday life after gastric bypass and duodenal switch
Abrahamsson, N., Engström, B. E., Sundbom, M., & Karlsson, F. A. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-0821 · Cited by 64 · see citing works
Diagnostic tools for post‐gastric bypass hypoglycaemia
Emous, M., Ubels, F. L., & van Beek, A. P. (2015) · Obesity Reviews · doi:10.1111/obr.12307 · Cited by 58 · see citing works
“In contrast to type 1 diabetes patients who have non-severe hypoglycaemic events one to two times per week (12,13), the frequency of hypoglycaemia after gastric bypass surgery in affected patients can be much higher, with episodes often occurring several times a day (14).”
BackgroundPostprandial hyperinsulinemic hypoglycemia after Roux-en-Y gastric bypass: an update.
Øhrstrøm, C., Worm, D., & Hansen, D. (2017) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2016.09.025 · Cited by 41 · see citing works
“Studies with MTTs have shown reversed hypoglycemia but persistent hyperglycemia following administration of a somatostatin analogue, whereas CGM readings following long term octreotide treatment showed tight glycemic control in a single individual((45,46)).”
BackgroundPost‐gastric bypass hypoglycaemia: a review
Shantavasinkul, P. C., Torquati, A., & Corsino, L. (2016) · Clinical Endocrinology · doi:10.1111/cen.13033 · Cited by 39 · see citing works
Postbariatric surgery hypoglycemia: Nutritional, pharmacological and surgical perspectives
Rossini, G., Risi, R., Monte, L., Sancetta, B. M., Quadrini, M., Ugoccioni, M., Masi, D., Rossetti, R., D’Alessio, R., Mazzilli, R., et al. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3750 · Cited by 34 · see citing works
Somatostatin analogues for the treatment of hyperinsulinaemic hypoglycaemia
Haris, B., Saraswathi, S., & Hussain, K. (2020) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820965068 · Cited by 41 · see citing works
Hazlehurst, J., Khoo, B. C. E., Lobato, C. B., Ilesanmi, I., Abbott, S., Chan, T. L., Pillai, S., Maslin, K., Purkayastha, S., McGowan, B. M., et al. (2024) · Endocrine Connections · doi:10.1530/ec-23-0285 · Cited by 43 · see citing works
“With regard to PBH (Table 9), short-acting SC octreotide and pasireotide (99, 120 ) appear to be effective at preventing hypoglycaemia following OGTT or MMT. IM long-acting pasireotide is also effective, although SC pasireotide three times a day may be more effective than long-acting IM pasireotide…”
Successful Medical Treatment of Adult Nesidioblastosis With Pasireotide over 3 Years: A Case Report
Schwetz, V., Horvath, K., Kump, P., Lackner, C., Perren, A., Forrer, F., Pieber, T. R., Treiber, G., Sourij, H., & Mader, J. K. (2016) · Medicine · doi:10.1097/md.0000000000003272 · Cited by 25 · see citing works
“Another factor in the avoidance of severe hypoglycemia achieved by pasireotide might be its suppression of GLP-1, as suggested by de Heide.9 Another effect of pasireotide rendering it successful in the treatment of neuroendocrine tumors could be its direct and indirect antitumor effects mediated via SSTR, such as apop…”
BackgroundResultInfluentialBantle, A., Wang, Q., & Bantle, J. P. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1283 · Cited by 23 · see citing works
“Noninvasive treatments include low-carbohydrate diets (5, 6), coingestion of the medication acarbose with meals containing carbohydrate to retard carbohydrate digestion (17, 18), treatment in a single patient with the somatostatin analog pasireotide (19), and continuous infusion of the GLP-1 receptor antagonist exendi…”
BackgroundA Low Dose of Pasireotide Prevents Hypoglycemia in Roux-en-Y Gastric Bypass-Operated Individuals
Øhrstrøm, C., Hansen, D., Kielgast, U., Hartmann, B., Holst, J., & Worm, D. (2019) · Obesity Surgery · doi:10.1007/s11695-019-04248-x · Cited by 21 · see citing works
Effects of GLP-1 on counter-regulatory responses during hypoglycemia after GBP surgery.
Almby, K., Abrahamsson, N., Lundqvist, M., Hammar, U., Thombare, K., Panagiotou, A., Karlsson, F., Sundbom, M., Wiklund, U., & Eriksson, J. C. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0171 · Cited by 21 · see citing works
Dumping Syndrome and Postbariatric Hypoglycemia: Supporting Evidence for a Common Etiology.
Furth, A. V., de Heide, L. D., Emous, M., Veeger, N., & van Beek, A. V. (2021) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2021.05.020 · Cited by 19 · see citing works
Hypoglycemia after gastric bypass: An emerging complication
Millstein, R., & Lawler, H. M. (2017) · Cleveland Clinic journal of medicine · doi:10.3949/ccjm.84a.16064 · Cited by 19 · see citing works
de Heide, L. J. M., Wouda, S. H. T., Peters, V. J. T., Oosterwerff‐Suiker, M., Gerdes, V. A., Emous, M., & van Beek, A. P. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14920 · Cited by 15 · see citing works
“4] Total weight loss (%) 34 [26-41] T2D, n (%) 22 (18.”
BackgroundCongenital hyperinsulinism: Global and Japanese perspectives
Yorifuji, T., Masue, M., & Nishibori, H. (2014) · Pediatrics International · doi:10.1111/ped.12390 · Cited by 15 · see citing works
Pasireotide treatment for severe congenital hyperinsulinism due to a homozygous ABCC8 mutation
Mooij, C., Tacke, C. E., van Albada, M. V., Barthlen, W., Bikker, H., Mohnike, K., Oomen, M., van Trotsenburg, A. V., & Zwaveling-Soonawala, N. (2021) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2142010.005 · Cited by 12 · see citing works
Somatostatin receptors in congenital hyperinsulinism: Biology to bedside
van Albada, M. V., Mohnike, K., Dunne, M., Banerjee, I., & Betz, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.921357 · Cited by 10 · see citing works
Juliana, C., Chai, J.-H., Arroyo, P., Rico-Bautista, E., Betz, S., & León, D. D. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104816 · Cited by 5 · see citing works
Post-Gastric Bypass Hypoglycemia: Diagnosis and Management
Fischer, L. E., Belt-Davis, D. I., Khoraki, J., & Campos, G. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-27114-9_21 · Cited by 5 · see citing works
Rouland, A., Bouillet, B., Legris, P., Simoneau, I., Petit, J., & Vergès, B. (2021) · Clinical Pharmacology : Advances and Applications · doi:10.2147/cpaa.s278978 · Cited by 4 · see citing works
“Nesiodioblastosis can occur after bariatric surgery, especially after Roux-en-Y gastric by-pass, maybe because of an increase of post-operative GLP1 secretion which can promote pancreatic beta cells hyperplasia.(2) Treatment of inappropriate insulin secretion is not always simple.”
BackgroundPostoperatives Management nach bariatrischen Operationen
Berger, H., Ordemann, J., Elbelt, U., Hofmann, T., & Menenakos, C. (2017) · Springer eBooks · doi:10.1007/978-3-662-48698-6_14 · Cited by 3 · see citing works
Managing post-bariatric hypoglycemia: a systematic review of pharmacological therapies
Sridharan, K., & Sivaramakrishnan, G. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01988-y · Cited by 1 · see citing works
Yukina, M., Chernova, M. O., Troshina, E., Evdoshenko, V., & Platonova, N. (2020) · Almanac of Clinical Medicine · doi:10.18786/2072-0505-2021-49-030 · Cited by 1 · see citing works
Postprandial Hyperinsulinemic Hypoglycemia in Bariatric Surgery
de Heide, L. D., Emous, M., & van Beek, A. V. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-804011-9.00054-6 · Cited by 1 · see citing works
Конопацкая, В. В., & Мохорт, Т. В. (2026) · Хирургия. Восточная Европа · doi:10.34883/pi.2026.15.2.022
Early and Late Dumping Syndromes
Mattar, S., & Rogers, A. (2019) · The ASMBS Textbook of Bariatric Surgery · doi:10.1007/978-3-030-27021-6_23
- Authors
- de Heide, L. J. M., Laskewitz, A. J., & Apers, J. A.
- Affiliations
- Medisch Centrum Leeuwarden (NL)
- Venue
- Surgery for Obesity and Related Diseases
- Publisher
- Elsevier BV
- Published
- 2014-05
- Volume
- 10
- Issue
- 3
- Pages
- e31-e33
- ISSN
- 1550-7289 (ISSN-L)
- OpenAlex
- W2038150921
- Cited by
- 33
- References
- 13
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 3 · 2022: 3 · 2021: 4 · 2020: 1 · 2019: 4 · 2017: 3 · 2016: 6 · 2015: 3 · 2014: 2
- FWCI
- 3.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Surgery for Obesity and Related Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- Roux-en-Y gastric bypass
- MeSH terms
- Blood Glucose, Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Follow-Up Studies, Gastrointestinal Agents, Glucagon, Humans, Hyperglycemia, Hyperinsulinism, Hypoglycemic Agents, Insulin, Middle Aged, Obesity, Morbid, Severity of Illness Index, Octreotide, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
